JP2003527861A - 増強した抗血液凝固能を持つ抗組織因子抗体 - Google Patents

増強した抗血液凝固能を持つ抗組織因子抗体

Info

Publication number
JP2003527861A
JP2003527861A JP2001569367A JP2001569367A JP2003527861A JP 2003527861 A JP2003527861 A JP 2003527861A JP 2001569367 A JP2001569367 A JP 2001569367A JP 2001569367 A JP2001569367 A JP 2001569367A JP 2003527861 A JP2003527861 A JP 2003527861A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
seq
sequence
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001569367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003527861A5 (https=
Inventor
キルヒホファー，ダニエル，ケイ．
ロウ，デイビッド，ジー．
プレスタ，レオナード，ジー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003527861A publication Critical patent/JP2003527861A/ja
Publication of JP2003527861A5 publication Critical patent/JP2003527861A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001569367A 2000-03-16 2001-03-08 増強した抗血液凝固能を持つ抗組織因子抗体 Pending JP2003527861A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18977500P 2000-03-16 2000-03-16
US60/189,775 2000-03-16
PCT/US2001/007501 WO2001070984A2 (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency

Publications (2)

Publication Number Publication Date
JP2003527861A true JP2003527861A (ja) 2003-09-24
JP2003527861A5 JP2003527861A5 (https=) 2008-05-01

Family

ID=22698717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001569367A Pending JP2003527861A (ja) 2000-03-16 2001-03-08 増強した抗血液凝固能を持つ抗組織因子抗体

Country Status (6)

Country Link
EP (1) EP1263960A2 (https=)
JP (1) JP2003527861A (https=)
AU (2) AU2001250814B2 (https=)
CA (1) CA2402596A1 (https=)
HK (1) HK1049184A1 (https=)
WO (1) WO2001070984A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541733A (ja) * 2005-05-26 2008-11-27 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
WO2015115656A1 (ja) * 2014-02-03 2015-08-06 独立行政法人国立がん研究センター 抗Ｔｉｓｓｕｅ Ｆａｃｔｏｒモノクローナル抗体
WO2019087994A1 (ja) * 2017-10-30 2019-05-09 国立研究開発法人国立がん研究センター 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT833911E (pt) 1995-06-07 2004-09-30 Ortho Mcneil Pharm Inc Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
GB0027750D0 (en) 2000-11-14 2000-12-27 Trisport Ltd Studded footwear
US20040180051A1 (en) * 2001-03-26 2004-09-16 Koji Suzuki Blood rheology improving agents
KR20040045478A (ko) * 2001-10-02 2004-06-01 노보 노르디스크 에이/에스 인간 조직인자 항체
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AP2004003113A0 (en) * 2002-02-22 2004-09-30 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
HK1080372A1 (zh) * 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
WO2004041302A1 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2005000896A2 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US20050031615A1 (en) * 2003-05-30 2005-02-10 Anderson G. Mark Method of inhibiting tumor growth with anti-tissue factor antibodies
CA2530980A1 (en) * 2003-06-19 2005-01-20 Tanox, Inc. Tissue factor-specific antibodies for preventing or treating acute lung injury or acute respiratory distress syndrome
US6904707B2 (en) 2003-07-01 2005-06-14 Softspikes, Llc Indexable shoe cleat with improved traction
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US20140296139A1 (en) 2013-03-15 2014-10-02 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
BR112023000455A2 (pt) * 2020-07-10 2023-03-28 Iconic Therapeutics Inc Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
WO2024102818A1 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Combination tumor therapy with thrombosis initiation and platelet recruitment
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040408A1 (en) * 1997-03-10 1998-09-17 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
WO1999051743A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596065A (en) * 1897-12-28 Ejector for ashes
DE3237880A1 (de) * 1982-10-13 1984-04-19 Robert Bosch Gmbh, 7000 Stuttgart Kodierspeicher, insbesondere fuer werkstuecktraeger in der fliessfertigung
JPS60188045A (ja) * 1984-03-08 1985-09-25 リサーチ・コーポレイシヨン 保存安定性魚肉ベース製品
US5811248A (en) * 1986-03-31 1998-09-22 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040408A1 (en) * 1997-03-10 1998-09-17 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
WO1999051743A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541733A (ja) * 2005-05-26 2008-11-27 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
US8492531B2 (en) 2005-05-26 2013-07-23 Genentech, Inc. Nucleic acids encoding humanized anti-CD40 antibodies
WO2015115656A1 (ja) * 2014-02-03 2015-08-06 独立行政法人国立がん研究センター 抗Ｔｉｓｓｕｅ Ｆａｃｔｏｒモノクローナル抗体
JP5957637B2 (ja) * 2014-02-03 2016-07-27 国立研究開発法人国立がん研究センター 抗ＴｉｓｓｕｅＦａｃｔｏｒモノクローナル抗体
US9920133B2 (en) 2014-02-03 2018-03-20 National Cancer Center Anti-tissue factor monoclonal antibody
WO2019087994A1 (ja) * 2017-10-30 2019-05-09 国立研究開発法人国立がん研究センター 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤
JPWO2019087994A1 (ja) * 2017-10-30 2020-11-12 国立研究開発法人国立がん研究センター 固形腫瘍の治療に有益な抗体およびその抗体−薬物コンジュゲート並びにこれらを含む抗がん剤
US11377504B2 (en) 2017-10-30 2022-07-05 National Cancer Center Japan Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
JP2023103439A (ja) * 2017-10-30 2023-07-26 国立研究開発法人国立がん研究センター 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤

Also Published As

Publication number Publication date
WO2001070984A3 (en) 2002-02-28
WO2001070984A2 (en) 2001-09-27
AU5081401A (en) 2001-10-03
AU2001250814B2 (en) 2007-02-15
EP1263960A2 (en) 2002-12-11
CA2402596A1 (en) 2001-09-27
HK1049184A1 (zh) 2003-05-02

Similar Documents

Publication Publication Date Title
JP2003527861A (ja) 増強した抗血液凝固能を持つ抗組織因子抗体
US6703494B2 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
AU2001250814A1 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
JP5184367B2 (ja) 抗アルファ２インテグリン抗体およびその使用
US20140050727A1 (en) Anti-cd14 antibody fusion protein
AU2017236063B2 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
US20110217318A1 (en) Anti-platelet membrane glycoprotein vi monoclonal antibody
TWI802193B (zh) 抗凝血因子ｘｉ抗體
AU2016201230A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US20160297892A1 (en) Novel Methods and Antibodies for Treating Coagulapathy
US10144784B2 (en) Monoclonal antibodies against antithrombin beta
EP3109320B1 (en) New anti-human pai-1 antibody
US20030124117A1 (en) Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US20030143225A1 (en) Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US7858089B2 (en) Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity
US20090214563A1 (en) Treatment for antiphospholipid-syndrome-related pregnancy complications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111011